Press Release February 17, 2022 The merger of Cerba Research and Viroclinics-DDL Together, transforming diagnostics for clinical trials. After the acquisition of Viroclinics-DDL by the group Cerba Healthcare, we are delighted to announce that Cerba Research, the...
PRESS RELEASE Cerba Healthcare enters agreement to acquire Viroclinics-DDL expanding and transforming its offering in clinical trials Acquisition illustrates the Group’s strategy to strengthen its position in the entire value chain of diagnosis and stresses the...
PRESS RELEASE Viroclinics-DDL and CEPI strengthen partnership with the production of Omicron SARS-CoV-2 variant for distribution in the CEPI COVID-19 Vaccine Testing Network ROTTERDAM, Netherlands and OSLO, Norway, 14 December 2021: Today, Viroclinics-DDL, a global...
Launching our new business unit Viroclinics Xellerate Viroclinics-DDL, today (September 3rd, 2021) announced the launch of Viroclinics Xellerate, a newly formed Business Unit focused on clinical trial support and global logistics services. Viroclinics Xellerate’s team...
PRESS RELEASE REPROCELL and VIROCLINICS-DDL Renew Collaboration Agreement in Clinical Research Rotterdam, The Netherlands, VIROCLINICS-DDL is pleased to announce the signing of a renewal for collaboration agreement with REPROCELL. REPROCELL will provide sample...
PRESS RELEASE ENPICOM and Viroclinics-DDL receive joint MIT R&D ZH subsidy to accelerate and improve antibody and vaccine discovery and development Partnership combines Viroclinics-DDL’s diagnostic and high-throughput sequencing experience with ENPICOM’s...
